Oncolytics Biotech® Reaches FDA Agreement on Pivotal Trial Design for Pelareorep in First-Line Pancreatic Cancer
Oncolytics Biotech® Aligns with FDA on Pivotal Phase 3 Study Design for Pelareorep in First-Line Metastatic Pancreatic Cancer Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy…
Tinostamustine Demonstrates Early Clinical Activity in Phase 1 Glioblastoma Study
Phase 1 Trial Reveals Promising Early Activity for Tinostamustine in Glioblastoma Purdue Pharma L.P. (“Purdue”) has announced encouraging preliminary data from its ongoing Phase 1 clinical study evaluating tinostamustine in…
Avenzo Therapeutics Names Scott Lipman as New Chief Financial Officer
Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer, Strengthening Executive Leadership to Advance Next-Generation Oncology Pipeline Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology…
KaliVir, Roche Partner to Test VET3-TGI + Tecentriq® in Advanced Tumors
KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company…
Boston Cell Standards Unveils Calibration Breakthrough to Enhance Accuracy in HER2-Low Breast Cancer Testing
Boston Cell Standards Announces Landmark CASI-01 Study in Lancet: eBioMedicine Demonstrating That Calibration Transforms Accuracy and Reproducibility in HER2-Low Breast Cancer Testing Boston Cell Standards today unveiled groundbreaking findings from…
Parse Biosciences Unveils FFPE-Compatible Single-Cell Barcoding Tech
Parse Biosciences Unveils Breakthrough FFPE-Compatible Barcoding Technology, Enabling Whole-Transcriptome Single-Cell Analysis from Archival Tissues Parse Biosciences, a global leader in scalable and accessible single-cell sequencing technologies, has announced a transformative…
Arrowhead Pharmaceuticals Gains FDA Nod for REDEMPLO®, a New Therapy Targeting Triglyceride Reduction in FCS
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran), Marking a Major Advancement in Treatment for Familial Chylomicronemia Syndrome Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced a landmark achievement today with the…
Lifordi Immunotherapeutics Gains Investment from Sanofi Ventures
Lifordi Immunotherapeutics Announces Major Strategic Investment Led by Sanofi Ventures, Strengthening Support from Existing Investors and Advancing a Transformative ADC Platform for Autoimmune and Inflammatory Diseases Lifordi Immunotherapeutics, Inc., a…
ChristianaCare Unveils New Organoid Core to Advance Personalized Cancer Therapies
ChristianaCare Establishes Organoid Core to Power Precision Cancer Treatment ChristianaCare’s Cawley Center for Translational Cancer Research has launched a groundbreaking organoid core—marking the first time such an advanced, patient-specific modeling…
FDA Approves POHERDY®, First US Biosimilar to PERJETA
Henlius and Organon Announce U.S. FDA Approval of POHERDY®, the First Interchangeable Pertuzumab Biosimilar in the United States Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced a major…
Nuvig Therapeutics Appoints Dr. Celia J.F. Lin to Lead as Chief Medical Officer
Nuvig Therapeutics Appoints Celia J.F. Lin, M.D., as Chief Medical Officer, Strengthening Clinical Leadership Amid Advancement of Novel Immunomodulatory Programs Nuvig Therapeutics, Inc. (“Nuvig”), a privately held biotechnology company focused…
Agenus Names Dr. José Iglesias as Chief Medical Affairs Officer
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Lead Global Strategy for BOT/BAL and Early-Access Programs Agenus Inc. (Nasdaq: AGEN), a biotechnology company recognized for its long-standing…